The Wall Street Journal
ZURICH -- Novartis AG said its leukemia drug Tasigna worked better than
the company's older product Gleevec in a clinical trial, underpinning
expectations that Novartis is positioning Tasigna to replace Gleevec
when the latter drug loses patent protection in 2015... Read More (access limited)
Find a Doctor/Researcher
Make an Appointment
Refer a Patient
Make a Gift
Penn Cancer Network
